Logo image of MDLA

Medallia Inc (MDLA) Stock Fundamental Analysis

NYSE:MDLA - New York Stock Exchange, Inc. -

33.99  +0.02 (+0.06%)

After market: 33.9999 +0.01 (+0.03%)

Fundamental Rating

3

Taking everything into account, MDLA scores 3 out of 10 in our fundamental rating. MDLA was compared to 284 industry peers in the Software industry. While MDLA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, MDLA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MDLA has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -14.41%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -34.44%
PM (TTM) -37.34%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

There is no outstanding debt for MDLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.71 indicates that MDLA is not a great score, but indicates only limited risk for bankruptcy at the moment.
MDLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 1.84 indicates that MDLA should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio N/A

More info and screens

6

3. Growth

3.1 Past

MDLA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -950.00%.
MDLA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.83%.
MDLA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.25% yearly.
EPS 1Y (TTM)-950%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
Revenue 1Y (TTM)18.83%
Revenue growth 3Y22.25%
Revenue growth 5YN/A
Sales Q2Q%24.74%

3.2 Future

The Earnings Per Share is expected to grow by 91.00% on average over the next years. This is a very strong growth
Based on estimates for the next years, MDLA will show a very strong growth in Revenue. The Revenue will grow by 20.67% on average per year.
EPS Next Y-682.76%
EPS Next 2Y-20.69%
EPS Next 3Y60.67%
EPS Next 5Y91%
Revenue Next Year20.49%
Revenue Next 2Y19.81%
Revenue Next 3Y21.03%
Revenue Next 5Y20.67%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MDLA Yearly Revenue VS EstimatesMDLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
MDLA Yearly EPS VS EstimatesMDLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0 0.2 0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MDLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 1801.27, the valuation of MDLA can be described as expensive.
The average S&P500 Price/Forward Earnings ratio is at 22.13. MDLA is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 1801.27
MDLA Price Earnings VS Forward Price EarningsMDLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 500 1K 1.5K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -49.39
MDLA Per share dataMDLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

MDLA's earnings are expected to grow with 60.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.69%
EPS Next 3Y60.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Medallia Inc

NYSE:MDLA (10/28/2021, 8:53:36 PM)

After market: 33.9999 +0.01 (+0.03%)

33.99

+0.02 (+0.06%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.34%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.47B
Analysts60
Price Target34.68 (2.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1801.27
P/S 10.43
P/FCF N/A
P/OCF N/A
P/B 15.34
P/tB N/A
EV/EBITDA -49.39
EPS(TTM)-0.17
EYN/A
EPS(NY)0.02
Fwd EY0.06%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.26
BVpS2.22
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -34.44%
PM (TTM) -37.34%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio N/A
Altman-Z 2.71
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-950%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
EPS Next Y-682.76%
EPS Next 2Y-20.69%
EPS Next 3Y60.67%
EPS Next 5Y91%
Revenue 1Y (TTM)18.83%
Revenue growth 3Y22.25%
Revenue growth 5YN/A
Sales Q2Q%24.74%
Revenue Next Year20.49%
Revenue Next 2Y19.81%
Revenue Next 3Y21.03%
Revenue Next 5Y20.67%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A